For a symptomatic post‑menopausal woman without contraindications, should I use Bijuva (estradiol + micronized progesterone) or Femoston (estradiol + dydrogesterone) for hormone therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bijuva vs Femoston for Menopausal Hormone Therapy

For a symptomatic postmenopausal woman with a uterus and without contraindications, choose Bijuva (estradiol + micronized progesterone) over Femoston (estradiol + dydrogesterone) based on the superior safety profile of micronized progesterone, particularly regarding cardiovascular and breast cancer risk.

Guideline-Based Recommendation

The 2017 AACE/ACE guidelines explicitly state that "when the use of progesterone is necessary, micronized progesterone is considered the safer alternative" 11. This recommendation directly addresses your choice between these two formulations, as Bijuva contains micronized progesterone while Femoston contains dydrogesterone (a synthetic progestogen).

The 2015 Endocrine Society guidelines recommend that for women with moderate cardiovascular risk, transdermal estradiol combined with micronized progesterone (or another progestogen that does not adversely modify metabolic parameters) should be first-line treatment because these preparations have fewer adverse effects 2.

Key Differentiating Factors

Progestogen Component - The Critical Distinction

  • Micronized progesterone (in Bijuva) is bioidentical to endogenous progesterone and appears to have:

    • Lower thrombotic risk compared to synthetic progestins 11
    • More favorable metabolic profile 2
    • Potentially lower breast cancer risk 34
    • Additional sleep quality benefits 5
  • Dydrogesterone (in Femoston) is a synthetic progestogen that, while generally well-tolerated, lacks the explicit guideline endorsement given to micronized progesterone 67

Cardiovascular Considerations

Recent evidence from 2026 confirms that transdermal estradiol is associated with lower venous thromboembolism risk than oral estrogen, and micronized progesterone may offer additional cardiovascular advantages 4. A 2026 comparative study showed Femoston significantly increased HDL-C (favorable) but also increased triglycerides (less favorable), whereas these lipid changes were not seen with similar regimens 8.

Efficacy Data

Both formulations effectively reduce vasomotor symptoms:

  • Bijuva demonstrated statistically significant reductions in both frequency and severity of moderate-to-severe hot flashes at weeks 4 and 12 compared to placebo 9910
  • Femoston has extensive literature supporting effective symptom relief and high amenorrhea rates 68

The efficacy is essentially equivalent between the two options.

Clinical Algorithm for Decision-Making

Start with Bijuva (estradiol + micronized progesterone) as first-line unless:

  1. Patient has specific lipid concerns requiring HDL elevation → Consider Femoston may provide HDL benefit 8
  2. Patient has hypertriglyceridemia → Avoid Femoston (increases TG); use Bijuva 8
  3. Patient requires antiandrogenic effects (hirsutism, acne) → Femoston with dydrogesterone may be preferable 8
  4. Patient has sleep disturbances → Bijuva with micronized progesterone offers additional sleep benefits 5
  5. Patient has elevated cardiovascular or VTE risk → Strongly favor Bijuva with micronized progesterone 114

Important Caveats

  • Both products are FDA-approved and guideline-endorsed for women with a uterus 299
  • The AACE explicitly recommends against custom-compounded bioidentical hormones, but Bijuva is FDA-regulated and distinct from compounded products 1110
  • Dosing matters: Bijuva comes in 0.5mg/100mg or 1mg/100mg estradiol/progesterone; Femoston has multiple dose options including ultra-low doses 97
  • Both require endometrial surveillance if unscheduled bleeding occurs 2
  • Annual reassessment of continued need is mandatory 2

Bottom Line

Bijuva is the preferred choice based on the explicit guideline recommendation favoring micronized progesterone as the safer progestogen alternative, particularly for cardiovascular and metabolic safety 11. Femoston remains a reasonable alternative when specific clinical scenarios (HDL optimization, antiandrogenic needs) warrant its use, but it should not be the default first choice given current evidence hierarchy.

References

Guideline

american association of clinical endocrinologists and american college of endocrinology position statement on menopause-2017 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2017

Guideline

treatment of symptoms of the menopause: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Research

Reappraising the safety of menopausal hormone therapy for women-implications for the clinic.

The Journal of clinical endocrinology and metabolism, 2026

Research

Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review.

BJOG : an international journal of obstetrics and gynaecology, 2026

Research

Literature review of estradiol/dydrogesterone in perimenopausal and postmenopausal women.

Climacteric : the journal of the International Menopause Society, 2026

Research

Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.